文献速递类风湿关节炎脊柱关节炎其他结缔组织病

IL-17受体A阻断剂brodalumab在炎症性疾病中的作用

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
PubMed 文献 · Rheumatology (Oxford) · 2016-01-01

本文综述靶向IL-17信号通路的治疗药物在炎症性疾病中的临床开发,重点讨论人抗IL-17受体A单克隆抗体brodalumab。早期临床研究(包括brodalumab、secukinumab和ixekizumab)的累积发现为IL-17信号在特定炎症性疾病病理生理中的作用提供了有力证据,并支持这些药物治疗这些疾病的潜力。

要点

  • IL-17信号通路是炎症性疾病治疗开发的吸引靶点。
  • brodalumab是人抗IL-17受体A单克隆抗体。
  • 早期抗IL-17药物研究支持IL-17信号在特定炎症性疾病中的作用。

核心结论

  • 早期临床研究累积发现为IL-17信号在特定炎症性疾病病理生理中的作用提供有力证据,并支持这些药物治疗这些疾病的潜力。

研究设计与样本

  • 本文为综述,聚焦靶向IL-17信号通路的治疗药物在炎症性疾病中的临床开发,重点讨论brodalumab。

主要发现

  • IL-17由多种细胞表达并介导针对胞外病原体的宿主防御。
  • IL-17在炎症部位上调,并可与TNF-α等其他细胞因子协同放大炎症反应。
  • 激活这些信号通路被假设参与银屑病、RA、PsA和哮喘等多种炎症性疾病的潜在发病机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IL-17 cytokines are expressed by a variety of cells and mediate host defence against extracellular pathogens. IL-17 is upregulated at sites of inflammation and can synergize with other cytokines, such as TNF-α, to amplify the inflammatory response. Activation of these signalling pathways has been hypothesized to contribute to the underlying pathogenesis of several inflammatory diseases, including psoriasis, RA, PsA and asthma. Thus the IL-17 signalling pathway is an attractive target for the development of therapeutic agents to modulate aberrant inflammatory responses. This review of the clinical development of therapeutic agents that target IL-17 signalling pathways in inflammatory diseases focuses on brodalumab, a human anti-IL-17 receptor A mAb. The cumulative findings of early clinical studies with anti-IL-17 agents, including brodalumab, secukinumab and ixekizumab, provide strong evidence for the role of IL-17 signalling in the pathophysiology of certain inflammatory diseases and support the potential use of these agents in treating these diseases.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nirula A, Nilsen J, Klekotka P, et al. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases. Rheumatology (Oxford). 2016. PMID: 27856660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。